USFDA approval to Zydus to market Teriflunomide tablets for MS relapse
Zydus group now has 237 approvals from the USFDA and has so far filed over 340 abbreviated new drug applications.
New Delhi: Drug firm Zydus Cadila recently said that it has received an approval from the US health regulator to market Teriflunomide tablets, used to treat relapsing forms of multiple sclerosis (MS). The company has received an approval from the United States Food and Drug Administration (USFDA) to market Teriflunomide Tablets - 7 mg and 14 mg - in the US market, Zydus Cadila said in a statement.
"It will be manufactured at the group's formulations manufacturing facility at special economic zone (SEZ), Ahmedabad," it added.
Teriflunomide is not a cure for MS but is thought to work by decreasing certain immune system cells (lymphocytes) which can attack the nerves in the brain and spinal cord.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd